Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Conditions
Interventions
Pamrevlumab
Placebo
Locations
125
United States
University of Alabama at Birmingham Hospital
Birmingham, Alabama, United States
Banner University Medical Center - Phoenix
Phoenix, Arizona, United States
Norton Thoracic Institute
Phoenix, Arizona, United States
Pulmonary Associates, PA - Research
Phoenix, Arizona, United States
University of Arizona
Tucson, Arizona, United States
J&L Research
Conway, Arkansas, United States
Start Date
June 18, 2019
Primary Completion Date
March 20, 2023
Completion Date
August 28, 2023
Last Updated
September 19, 2024
NCT06238622
NCT07299695
NCT07466420
NCT06241560
NCT07407543
NCT05989698
Lead Sponsor
Kyntra Bio
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions